75 results
Page 2 of 4
8-K
EX-99.1
mb2acu8hsqqmh4mnzx
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
wdluh1gvzouq
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
vcitxvq612
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.1
94jx71 q0g54ox983w
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.2
q8mk1dzn 9c
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
4f2gs1mc96xnyg
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
tvukic4h
16 May 22
Additional proxy soliciting materials
6:32pm
8-K
EX-99.1
jnyqxy8w9l1
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DEFA14A
38m4gygb qz
11 May 22
Additional proxy soliciting materials
4:49pm
DEFA14A
h9k 7xw1a1gxa0
9 May 22
Additional proxy soliciting materials
4:32pm
DEFA14A
2l84ix ftj47ldpr
5 May 22
Additional proxy soliciting materials
4:00pm
DEFA14A
1k82pqm0
5 May 22
Additional proxy soliciting materials
8:19am
DEFA14A
vuukmyw8
5 May 22
Additional proxy soliciting materials
8:15am
DEFA14A
j178qste1cbz5znk2rdv
26 Apr 22
Additional proxy soliciting materials
8:17am
DEFA14A
9kflba
26 Apr 22
Additional proxy soliciting materials
8:11am
DEFA14A
26he5k68k 0rrnid
20 Apr 22
Additional proxy soliciting materials
4:03pm
DEFA14A
pctjot4
11 Apr 22
Additional proxy soliciting materials
4:36pm
DEFC14A
cf7he89skih8 6j
11 Apr 22
Proxy in contested solicitation
8:36am